Focaccetti’s team [78] found that FL-DNAM-1-CD3z engineered NK cells combined with immunomodulatory drugs such as Nutlin3a could represent a new immunotherapeutic approach for the treatment of p53 dysfunctional neuroblastoma. This evidence concerns the gene CD226 and neuroblastoma.